医中誌リンクサービス


文献リスト

1)Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006; 6: 714-27
PubMed
医中誌リンクサービス
2)Gelderman KA, Tomlinson S, Ross GD, et al. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 2004; 25: 158-64
PubMed CrossRef
医中誌リンクサービス
3)Selenko N, Maidic O, Draxier S, et al. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia. 2001; 15: 1619-26
PubMed CrossRef
医中誌リンクサービス
4)Dhodapkar KM, Krasovsky J, Williamson B, et al. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med. 2002; 195: 125-33
PubMed CrossRef
医中誌リンクサービス
5)zum Buschenfelde CM, Hermann C, Schmidt B, et al. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res. 2002; 62: 2244-7
PubMed
医中誌リンクサービス
6)Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003; 22: 7359-68
PubMed CrossRef
医中誌リンクサービス
7)Hinoda Y, Sasaki S, Ishida T, et al. Monoclonal antibodies as effective therapeutic agents for solid tumors. Cancer Sci. 2004; 95: 621-5
医学中央雑誌刊行会  PubMed CrossRef
医中誌リンクサービス
8)Ashkenazi A. Targeting death and decoy receptors of the tumor-necrosis factor superfamily. Nat Rev Cancer. 2002; 2: 420-30
PubMed
医中誌リンクサービス
9)Creagan ET, Kovach JS, Moertel CG, et al. A phase I clinical trial of recombinant human tumor necrosis factor. Cancer. 1998; 62: 2467- 71
PubMed
医中誌リンクサービス
10)Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature. 1993; 364: 806-9
PubMed CrossRef
医中誌リンクサービス
11)Smyth MJ, Takeda K, Hayakawa Y, et al. Nature's TRAIL--on a path to cancer immunotherapy. Immunity. 2003; 18: 1-6
PubMed CrossRef
医中誌リンクサービス
12)Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995; 3: 673-82
PubMed CrossRef
医中誌リンクサービス
13)Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996; 271: 12687-90
PubMed CrossRef
医中誌リンクサービス
14)Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999; 5: 157-63
PubMed CrossRef
医中誌リンクサービス
15)Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999; 104: 155-62
PubMed
医中誌リンクサービス
16)Takeda K, Smyth MJ, Cretney E, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med. 2002; 195: 161-9
PubMed CrossRef
医中誌リンクサービス
17)Cretney E, Takeda K, Yagita H, et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol. 2002; 168: 1356-61
PubMed
医中誌リンクサービス
18)Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004; 21: 137-48
PubMed CrossRef
医中誌リンクサービス
19)Schneider P, Olson D, Tardivel A, et al. Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem. 2003; 278: 5444-54
PubMed CrossRef
医中誌リンクサービス
20)Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997; 277: 818-21
PubMed CrossRef
医中誌リンクサービス
21)Mori E, Thomas M, Motoki K, et al. Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell Death Differ. 2004; 11: 203-7
PubMed CrossRef
医中誌リンクサービス
22)Hayakawa Y, Screpanti V, Yagita H, et al. NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J Immunol. 2004; 172: 123-9
PubMed
医中誌リンクサービス
23)Chuntharapai A, Dodge K, Grimmer K, et al. Isotype-dpendent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol. 2001; 166: 4891-8
PubMed
医中誌リンクサービス
24)Ichikawa K, Liu W, Zhao L, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med. 2001; 7: 954-60
PubMed CrossRef
医中誌リンクサービス
25)Takeda K, Yamaguchi N, Akiba H, et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med. 2004; 199: 437-48
PubMed CrossRef
医中誌リンクサービス
26)Rowinsky EK. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol. 2005; 23: 9394-407
PubMed CrossRef
医中誌リンクサービス
27)LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 2003; 10: 66-75
PubMed CrossRef
医中誌リンクサービス
28)Yagita H, Takeda K, Hayakawa Y, et al. TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 2004; 95: 777-83
医学中央雑誌刊行会  PubMed CrossRef
医中誌リンクサービス
29)Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999; 5: 677-85
PubMed CrossRef
医中誌リンクサービス
30)Allison JP, Hurwitz AA, Leach DR. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol. 1995; 7: 682-6
PubMed CrossRef
医中誌リンクサービス
31)Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol. 2003; 3: 609-20
PubMed
医中誌リンクサービス
32)Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007; 7: 95-106
PubMed
医中誌リンクサービス
33)Diehl L, den Boer AT, Schoenberger SP, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med. 1999; 5: 774-9
PubMed CrossRef
医中誌リンクサービス
34)French RR, Chan HT, Tutt AL, et al. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med. 1999; 5: 548-53
PubMed CrossRef
医中誌リンクサービス
35)Sotomayor EM, Borrello I, Tubb E, et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med. 1999; 5: 780-7
PubMed CrossRef
医中誌リンクサービス
36)Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997; 3: 682-5
PubMed CrossRef
医中誌リンクサービス
37)Uno T, Takeda K, Kojima Y, et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med. 2006; 12: 693-8
PubMed CrossRef
医中誌リンクサービス
38)Basombrio MA. Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene. Cancer Res. 1970; 30: 2458-62
PubMed
医中誌リンクサービス
39)Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape" phenotypes. Nat Immunol. 2002; 3: 999-1005
PubMed CrossRef
医中誌リンクサービス
40)Takeda K, Stagg J, Yagita H, et al. Trageting death-inducing receptors in cancer therapy. Oncogene. 2007; 26: 3745-57
PubMed CrossRef
医中誌リンクサービス
41)Takeda K, Okumura K, Smyth MJ. Combination antibody-based cancer immunotherapy. Cancer Sci. 2007; 98: 1297-302
PubMed CrossRef
医中誌リンクサービス


NPO医学中央雑誌刊行会
https://www.jamas.or.jp/
info@jamas.or.jp